Table 3.

Hazard Ratios (HR) for Incident Anemia and Anthropometric Outcomes Among Individuals With Versus Those Without Hypoalbuminemia at Baseline

Outcome (No. of Events)	Crude HR (95% CI)	P	Adjusted HRa (95% CI)	P
Severe anemiab (179)	2.61 (1.94–3.50)	<.001	2.28 (1.67–3.10)	<.001
Anemiac (153)	1.78 (1.23–2.58)	.002	1.42 (.96–2.12)	.081
Wastingd (175)	2.03 (1.51–2.74)	<.001	1.69 (1.22–2.35)	.002
>10% weight losse (278)	1.44 (1.13–1.83)	.003	1.40 (1.08–1.82)	.012

Hypoalbuminemia was defined as a serum albumin concentration of <35 g/L. Individuals with outcome events at baseline were excluded from analyses.

Abbreviations: AZT, zidovudine; BMI, body mass index (calculated as the weight in kilograms divided by the height in meters squared); CI, confidence interval; d4T, stavudine; EFV, efavirenz; HIV, human immunodeficiency virus; NVP, nevirapine; WHO World Health Organization; 3TC, lamivudine.

^a Adjusted for sex and baseline age (30, 30–39, 40–49, and ≥50 years), WHO HIV disease stage (I/II, III, and IV), CD4⁺ T-cell count (<50, 50–99, 100–199, and ≥200 cells/μL), and alanine transaminase level (≤40 and >40 IU/L), for all outcomes; baseline BMI (<16.0, 16.0–18.4, 18.5–25.0, and >25.0), for anemia only; baseline hemoglobin level (<8.5, 8.5–11, and ≥11 g/dL), for wasting only; and baseline height, for wasting and >10% weight loss only.

^b Defined as a hemoglobin level of <85 g/L for men and women.

^c Defined as a hemoglobin level of <120 g/L for women and <130 g/L for men.

^d Defined as a BMI of <18.5 kg/m².

^e Defined as a >10% decrease from baseline.